Introduction {#Sec1}
============

Ovarian cancer is the second most common gynaecological cancer and accounts for more deaths than any other cancer of the female reproductive system \[[@CR1]\]. Despite optimal multivisceral cytoreductive surgery and standard platinum-based first-line chemotherapy, the majority of patients will suffer from a relapse within the first 2--3 years. Therefore, improved strategies to identify patients at risk for recurrence are urgently needed. In this context, blood-based biomarkers such as circulating tumor cells (CTCs) have emerged as a promising candidate.

Hematogenous dissemination of cancer cells shed by the primary tumor is a common phenomenon observed in several solid malignancies \[[@CR2]--[@CR4]\]. While blood-borne disease spread leading to development of distant metastases frequently occurs in entities such as breast, prostate and lung cancer, gynaecological tumors are more likely to show continuous spread within the abdominal cavity. Interestingly, based on clinical studies, isolated tumor cells can be detected in blood and bone marrow samples of patients with ovarian cancer with similar positivity rates as in breast cancer \[[@CR5]--[@CR7]\]. In a large pooled analysis of 495 patients with primary ovarian cancer disseminated tumor cells in bone marrow were detected in 27% of patients and predicted significantly shorter overall survival (OS) \[[@CR6]\]. Since blood sampling is less invasive and allows serial measurements, the focus of translational research has shifted from disseminated tumor cells to CTCs in peripheral blood. Presence of two or more CTCs have already been shown to be associated with an unfavourable prognosis in relapsed ovarian cancer \[[@CR7]\].

The aim of the present study was (1) to evaluate the prognostic relevance of CTCs at time of diagnosis and (2) to examine the dynamics of CTCs during chemotherapy in patients with ovarian, fallopian tube and peritoneal cancer.

Methods {#Sec2}
=======

43 patients from two certified Gynaecological Cancer Centers were enrolled in this prospective, open-label, non-randomized study. 34 patients were diagnosed with ovarian cancer, five with fallopian tube cancer and four with primary peritoneal cancer. Patients were scheduled to receive chemotherapy in the first-line (*n* = 23) or higher-line (*n* = 20) setting. Further inclusion criteria were: age 18 years and older, and diagnosis of primary or relapsed ovarian, fallopian tube or peritoneal cancer. Blood samples were collected before start of a new line of chemotherapy chosen according to national and institutional standards as well as after three and six cycles of therapy. Response to therapy was evaluated according to institutional guidelines, mostly by CT scan and CA125 determination. Informed consent was obtained from all individual participants included in the study.

Detection of CTCs {#Sec3}
-----------------

CTCs were detected using the CellSearch™ system (formerly Veridex LLC, NJ, USA, now Menarini Silicon Biosystems, Italy). Briefly, 7.5 ml peripheral blood were collected into CellSave Tubes and processed according to manufacturer's instructions. The assay consists of an immunomagnetic enrichment step employing immunomagnetic beads coated with anti-epithelial cell adhesion molecule (EpCAM) antibody, followed by staining with several antibodies. A circulating tumor cell is defined as a CD45-negative cytokeratin-positive cell with a DAPI-stained nucleus. In the current study, CTC-positive patients were defined as those with at least one tumor cell per 7.5 ml blood.

Statistical analysis {#Sec4}
--------------------

Chi-squared test were used to evaluate the relationship between CTC detection and clinical-pathological factors. In the survival analysis, following primary end points were considered: (1) death and (2) progression. Survival intervals were measured from the time of blood sampling to the time of death or of the first clinical, histological or radiographic diagnosis of progression. We constructed Kaplan--Meier curves and used the log-rank test to assess the univariate significance of the parameters. Cox regression analysis was used for multivariate analysis. All reported p-values are two-sided. *p* values ≤ 0.05 were considered significant. Statistical analysis was performed by SPSS (SPSS Inc., Chicago, IL, USA). The analysis was performed according to the REporting recommendations for tumor MARKer prognostic studies (REMARK) criteria on reporting of biomarkers \[[@CR8]\]. The primary question was the prognostic impact of CTCs in the entire patient cohort.

Results {#Sec5}
=======

Patients' characteristics {#Sec6}
-------------------------

Clinical--pathological data of 43 patients enrolled in the study are summarized in Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}. Blood sample was collected at time of first diagnosis of malignant disease in 53% of patients, in the remaining 47% of cases at time of recurrent or progressive disease. The majority of patients had ovarian cancer (79%), followed by fallopian tube (12%) and peritoneal cancer (9%). Previous therapies received by patients with recurrent/progressive disease are shown in Table [3](#Tab3){ref-type="table"}. Details regarding therapy administered during study are shown in Tables [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"}. Among patients with primary disease, all but one received primary debulking surgery and were scheduled for adjuvant systemic treatment in accordance with current national treatment guidelines. In one case (Patient 40, Table [4](#Tab4){ref-type="table"}) with advanced disease and tumor rest \> 2 cm, the patient refused further blood sampling and received neoadjuvant systemic therapy followed by secondary laparotomy with hyperthermic intraperitoneal chemotherapy (HIPEC) at another hospital. The BRCA status of the tumor has been assessed in 10 patients with recurrent/progressive disease and revealed a somatic BRCA1 mutation in one case. The remaining nine patients had BRCA-negative tumors.Table 1Distribution of the study patients according to circulating tumor cells in correlation to clinical-pathological characteristicsTotalCTC positive at baseline *n* (%)*p* valueOverall4311 (26%)Cancer origin0.953 Ovarian cancer349 (27%) Fallopian tube cancer51 (20%) Primary peritoneal cancer41 (25%)Disease setting0.187 Newly diagnosed cancer234 (17%) Recurrence207 (35%)Histology0.331 Serous high-grade379 (24%) Serous low-grade21 (50%) Endometrioid20 (0%) Clear cell10 (0%) Undifferentiated (G4)11 (100%)Table 2Correlation of CTC status and established parameters in patients with newly diagnosed cancerTotalCTC positive at baseline *n* (%)*p* valueT stage0.191 T1-260 (0%) T3174 (24%)FIGO stage0.191 I--II60 (0%) III--IV174 (24%)Nodal status0.825^b^ Node-negative81 (13%) Node-positive61 (17%) Unknown^a^92 (22%)Residual tumor0.106 No (macroscopic complete resection)141 (7%) Yes93 (33%)Histology0.586 Serous high-grade193 (16%) Serous low-grade21 (50%) Endometrioid10 (0%) Clear cell10 (0%)^a^According to the national guidelines at time of surgical treatment the systematic lymphadenectomy was performed only when optimal cytoreduction has been achieved^b^Analysis performed for patients with known nodal statusTable 3Patients with recurrent/progressive disease at time of study enrollment: overview of therapiesPatient numberDisease setting during studyPrevious systemic therapySurgical therapy in the current disease settingTherapy during study1Third lineCarboplatin, paclitaxel, bevacizumabCarboplatin, gemcitabine, bevacizumab (within a clinical trial)NoCarboplatin, pegylated liposomal doxorubicin2Second lineCarboplatin, paclitaxel, bevacizumabYes, debulking before start of second line therapyPegylated liposomal doxorubicin, trabectedin3Forth lineCarboplatin, paclitaxelCarboplatin, paclitaxel, bevacizumabCarboplatin, paclitaxel, maintenance therapy with olaparibYes, debulking before start of forth line therapyPegylated liposomal doxorubicin, trabectedin4Fifth lineCarboplatin, paclitaxelCarboplatin, gemcitabineCarboplatin, gemcitabineCarboplatin, gemcitabineNoPegylated liposomal doxorubicin, trabectedin5Second lineCarboplatin, paclitaxel, bevacizumabNoPegylated liposomal doxorubicin, trabectedin6Second lineCarboplatin, paclitaxelNoCarboplatin7Second lineNo systemic therapy administered after surgeryYes, debulking before start of systemic therapyCarboplatin8Second lineCarboplatin, paclitaxel, bevacizumabYes, debulking before start of second line therapyCarboplatin, pegylated liposomal doxorubicin9Second lineCarboplatin, paclitaxel, bevacizumabNoCarboplatin, pegylated liposomal doxorubicin10Second lineCarboplatin, paclitaxel, bevacizumabNoCarboplatin, pegylated liposomal doxorubicin11Third lineCarboplatin, paclitaxel, bevacizumabCarboplatin, pegylated liposomal doxorubicin, bevacizumab (within a clinical trial)NoCarboplatin, pegylated liposomal doxorubicin, bevacizumab12Third lineCarboplatin, paclitaxelPegylated liposomal doxorubicin, trabectedinNoNone (best supportive care)13Second lineCarboplatin, paclitaxel, bevacizumabNoCarboplatin, paclitaxel14Third lineCarboplatin, paclitaxelPegylated liposomal doxorubicin, trabectedinNoCarboplatin, paclitaxel15Second lineNo systemic therapy administered after surgery (patient's refusal)NoCarboplatin, paclitaxel, bevacizumab16Fifth lineCarboplatin, paclitaxelCarboplatin, gemcitabine, bevacizumabPegylated liposomal doxorubicinTopotecanNoNone (best supportive care)17Third lineCarboplatin, paclitaxel, bevacizumabCarboplatin, pegylated liposomal doxorubicinNoPaclitaxel18Third lineCarboplatin, paclitaxelPegylated liposomal doxorubicinNoTopotecan19Fifth lineCarboplatin, paclitaxelCarboplatin, gemcitabinePegylated liposomal doxorubicin, trabectedinTopotecanNoTopotecan20Second lineUnknown (first-line therapy administered abroad)NoNone (best supportive care)Table 4Patients with primary disease at time of study enrollment: overview of therapiesPatient numberTherapy during studyChemotherapy administered as planned21Carboplatin, paclitaxel, bevacizumabYes22Carboplatin, paclitaxel, bevacizumabYes23Carboplatin, paclitaxel, bevacizumabYes24Carboplatin, paclitaxel, bevacizumabYes25Carboplatin, paclitaxel, bevacizumabYes261 cycle of carboplatin, paclitaxel, followed by 6 cycles of carboplatin weeklyNo, switch to weekly monotherapy due to reduced performance status27Carboplatin, paclitaxelYes28None (best supportive care)29Carboplatin, paclitaxel, bevacizumabYes30Carboplatin, paclitaxel, bevacizumabYes31Carboplatin, paclitaxelYes32Carboplatin, paclitaxelYes33Carboplatin, paclitaxelYes34Carboplatin, paclitaxelYes35Carboplatin, paclitaxelYes36None (best supportive care)37Carboplatin weeklyNo, therapy discontinuation due to adverse events after 3 cycles38Carboplatin, paclitaxel, bevacizumabYes39Carboplatin, paclitaxelYes40No therapy details availableNo, study discontinuation after the first blood samples (patient's request)41Carboplatin, paclitaxel, bevacizumabYes42Carboplatin, paclitaxel, bevacizumabYes43None (best supportive care)

Correlation of CTCs with clinical-pathological data {#Sec7}
---------------------------------------------------

In 26% of patients at least one CTC per 7.5 ml of peripheral blood was detected at baseline (range 0--76, mean 2.84). Presence of CTC at time of diagnosis was not associated with the tumor origin and established prognostic factors such as tumor stage or nodal status. CTC status did not correlate with macroscopic tumor rest. At least one CTC was detected in 17% of patients with de novo disease, compared to 35% in recurrent patients, however this difference was not statistically significant (*p* = 0.187). After three cycles of systemic therapy, the CTC positivity rate declined to 4.8%; all patients with primary cancer were CTC-negative at this time point. After six cycles of therapy, no patient showed persistent CTCs.

Survival analysis {#Sec8}
-----------------

After a median follow-up of 25 months (range 3--36 months), 18 patients died. Patients with at least one detectable CTC at baseline had significantly shorter OS compared to CTC-negative patients (mean OS 12.3 \[95% CI 4.4--20.1\] vs. 24.6 \[19.7--29.4\] months, median 3.1 \[0.0--12.0\] vs. not reached; *p* = 0.006, Fig. [1](#Fig1){ref-type="fig"}, Table [5](#Tab5){ref-type="table"}). When only the subgroup with newly diagnosed cancer was considered, the association between CTC status and survival was not significant (mean 17.4 \[1.7--33.1\] vs. 29.0 \[24.3--33.7\] months, *p* = 0.192, Fig. [2](#Fig2){ref-type="fig"}, Table [5](#Tab5){ref-type="table"}). Presence of at least one CTC after three cycles of systemic treatment predicted shorter OS in the entire patient cohort (mean OS 11.1 vs. 31.2 months, *p* \< 0.001). In the entire cohort, CTC-positive patients at baseline had median progression-free survival of 3.1 months, compared to 23.1 months in CTC-negative patients (*p* = 0.005, Fig. [1](#Fig1){ref-type="fig"}, Table [5](#Tab5){ref-type="table"}). In the multivariate analysis including CTC status, disease setting, histology and tumor rest, only the presence of CTCs significantly predicted reduced OS, while residual tumor and CTC status were the only independent factors predicting PFS (Table [6](#Tab6){ref-type="table"}).Fig. 1Kaplan--Meier plots of overall and progression-free survival according to CTC status in the entire patient cohortTable 5Univariate analysis of CTC status and overall and progression-free survival according to disease settingOverall survival (months)Progression-free survival (months)CTC-positive vs. CTC-negative*p* valueCTC-positive vs. CTC-negative*p* valueEntire cohort (*n* = 43)Mean12.3 \[95% CI 4.4---20.1\] vs. 24.6 \[19.7--29.4\]Median:3.1 \[0.0--12.0\] vs. NR0.006Mean10.6 \[3.8--17.4\] vs. 22.1 \[17.2--26.9\]Median:3.1 \[0.0--12.0\] vs. 23.1 \[13.1--33.1\]0.005Primary cancer (*n* = 23)Mean17.4 \[1.7--33.1\] vs. 29.0 \[24.3--33.7\]Median1.9 vs. NR0.192Mean14.3 \[1.0--27.7\] vs. 26.9 \[22.2--31.6\]Median2.0 \[0.0--21.9\] vs. NR0.085Recurrent/progressive disease (*n* = 20)Mean6.8 \[2.9--10.7\] vs. 13.0 \[6.3--19.7\]Median3.1 \[1.8--4.5\] vs. 11.1 \[2.6--19.6\]0.169Mean6.8 \[2.9--10.7\] vs. 11.7 \[5.5--17.9\]Median3.1 \[1.8--4.5\] vs. 4.9 \[0.0--14.0\]0.251*CI* confidence interval, *NR* not reachedFig. 2Kaplan--Meier plot of overall survival according to CTC status in the subgroup with primary non-relapsed cancerTable 6Multivariate analysis of overall and progression-free survivalParameterOverall survivalProgression-free survival*p* valueHazard ratio95% CI*p* valueHazard ratio95% CICTC status Positive vs. negative0.0183.4391.23--9.610.0024.3891.72--11.20Disease setting Primary vs. recurrent/progressive disease0.6180.6660.14--3.300.3272.0830.48--9.03Histology Serous high grade vs. other0.5911.4200.40--5.090.6491.2980.42--3.99Residual tumor No surgical therapy vs. macroscopic tumor rest vs. no tumor rest0.1672.1160.73--6.140.0035.0031.71--14.65*CI* confidence interval

Discussion {#Sec9}
==========

In the present study, we demonstrated that hematogenous dissemination is a common phenomenon in patients with ovarian, fallopian tube and primary peritoneal cancer. Using the CellSearch assay, CTCs were detected in one-fourth of enrolled patients. While this finding might be at first surprising---giving the preference of these tumor entities for local tumor growth within abdominal cavity---it confirms our previously published data on the presence of disseminated tumor cells in bone marrow of patients with gynaecological malignancies \[[@CR6]\]. In this prospective multicentre trial including 495 patients with primary ovarian cancer we reported a prevalence rate of disseminated tumor cells of 27%. Similar positivity rates were observed by others (Table [7](#Tab7){ref-type="table"}) \[[@CR9]--[@CR13]\]. Since bone marrow sampling involves an invasive procedure, the research focus has shifted to examination of peripheral blood over the last two decades and an increasing body of evidence on CTCs in the blood of ovarian cancer patients is available. The largest study to date was conducted in relapsed ovarian cancer. Poveda et al. detected CTCs using the same assay as in our study (CellSearch) and reported a significantly reduced progression-free and overall survival in CTC-positive patients \[[@CR7]\]. Interestingly, in contrast to other trials, Poveda et al. defined CTC-positivity as presence of two or more CTCs per 7.5 ml blood, so patients with one CTC were qualified as CTC-negative. Setting a specific cut-off value in case of CTC-based trials is common in other entities. For instance, in metastatic breast cancer several clinical trials used 5 CTCs per 7.5 ml blood as a threshold to differentiate between patients with favourable and unfavourable outcome \[[@CR14]--[@CR16]\], whereas 3 CTCs have been shown to be a more suitable cut-off value in metastatic colorectal cancer \[[@CR17]\].Table 7Prevalence and prognostic relevance of circulating and disseminated tumor cells at time of diagnosis in patients with ovarian, fallopian tube and peritoneal cancerStudyTumor entityTarget cells / AssayPositivity ratePrognostic relevanceOur studyPrimary and relapsed ovarian, fallopian tube and peritoneal cancerCTCsCellSearch26% (17% in primary, 25% in relapsed cancer)OS, PFS^a,b^Fehm, Banys et al. 2013 \[[@CR6]\]Primary ovarian cancerDTCsICC27%OS, PFS^b^Poveda et al. 2011 \[[@CR7]\]Relapsed ovarian cancerCTCsCellSearch14% (defined as ≥ 2 CTCs per 10 ml blood)OS, PFSBanys et al. \[[@CR5]\]^c^Primary ovarian cancerDTCsICC25%DFSZhang et al. \[[@CR22]\]Primary ovarian cancerCTCsImmunobeads, Multiplex-RT-PCR90%OS shorter in patients with EpCAM-positive CTCsBraun et al. \[[@CR12]\]^c^Primary ovarian cancerDTCsICC30%DFS, DDFS^b^, OSMarth et al. 2002 \[[@CR10]\]Primary ovarian cancerCTCsImmunobeads12%n.sDTCsImmunobeads21%n.sSchindlbeck et al. \[[@CR11]\]Primary ovarian cancerDTCsICC23%DDFSAktas et al. 2011 \[[@CR9]\]Primary ovarian cancerCTCsMultiplex-RT-PCR (AdnaTest)19%OSDTCsICC35%n.sChebouti et al. \[[@CR13]\]Primary ovarian cancerDTCsICC42%OSFan et al. \[[@CR18]\]Primary ovarian cancerCTCsImmunofluorescence and cell invasion assay61%DFSSehouli et al. \[[@CR19]\]Primary ovarian cancerCTCsICCn.an.s*CTCs* circulating tumor cells, *DDFS* distant disease-free survival, *DFS* disease-free survival, *DTCs* disseminated tumor cells, *ICC* immunocytochemistry, *OS* overall survival, *n.s.* not significant, *PFS* progression-free survival^a^Entire cohort, statistical significance in subgroups not reached^b^Multivariate analysis^c^Tthese cohorts were completely or partially included in the pooled analysis \[[@CR6]\]

While the prognostic relevance of hematogenous tumor cell dissemination was confirmed in large trials in entities such as breast cancer, data regarding ovarian cancer are still limited. In the present study presence of at least one CTC was associated with worse PFS and OS in the entire cohort. When patients with primary and relapsed cancer were considered as separate subgroups, the correlation was not significant. However, this trial was not powered for subgroup analysis. Similar results have been reported by several other studies. Positive CTC status, defined as ≥ 2 CTCs per 7.5 ml blood, predicted shorter progression-free survival and OS in patients with relapsed ovarian cancer \[[@CR7]\]. An association with OS or disease-free survival has been reported by two smaller studies conducted in primary ovarian cancer as well \[[@CR9], [@CR18]\]. However, a correlation with survival has not been shown by others, so far \[[@CR10], [@CR19]\]. Evidence is clearer with respect to tumor cell detection in the bone marrow: in the pooled analysis of individual patients data from three centers presence of disseminated tumor cells significantly predicted reduced survival \[[@CR6]\]. Several hypotheses were discussed as to the biological fate of the single tumor cells. While we cannot exclude the possibility that CTCs and disseminated tumor cells are solely an epiphenomenon of current tumor load, the available data suggest that their role is beyond being just a by-product without their own clinical relevance. Since patients with ovarian carcinoma rarely develop secondary bone metastases, bone marrow seems to serve as a temporary "compartment" for disseminated tumor cells, where they might stay dormant for prolonged periods of time \[[@CR20], [@CR21]\]. Subsequently, they might be able to leave their homing site and cause metastatic growth or locoregional recurrence \[[@CR6]\]. Hypothetically, these single cells might also be able to re-populate the abdominal cavity, where they encounter a microenvironment suitable to support ovarian cancer growth.

Possibly, not only the presence of CTCs, but their expression profiles may predict the clinical potential. Zhang et al. examined blood samples from 109 patients with newly diagnosed ovarian cancer using Multiplex-RT-PCR based on the detection of six cancer-related genes \[[@CR22]\]. While this assay yielded very high CTC detection rates of 90%, the survival analysis showed that only EpCAM positivity of CTCs predicted shorter OS. Interestingly, the CellSearch system, used in our study, includes an enrichment step based on anti-EpCAM antibodies. For that reason, CTCs detected by this assay are more likely to express EpCAM that those detected by other methods (Table [4](#Tab4){ref-type="table"}).

Although the majority of patients with primary ovarian carcinoma initially responds to (neo)adjuvant platinum-based chemotherapy, most will relapse following the state-of-the-art treatment \[[@CR23]\]. Therefore, strategies for identification of patients at high risk for relapse early during first-line therapy are urgently needed. In our study, the CTC positivity rate declined rapidly during treatment and no patient showed CTCs at the end of sixth cycle of chemotherapy. In the study by Zhang et al., CTC counts decreased during adjuvant and neoadjuvant therapy as well \[[@CR22]\]. Interestingly, peripheral blood was obtained both before and 7--14 days after surgery and a rapid increase in CTC counts has been observed between these two time points. Since the baseline blood sample in our study was collected after surgery, we do not know whether such a decline could be observed using the CellSearch detection system as well. In contrast, Aktas et al. evaluated blood samples from primary ovarian cancer patients obtained before surgery in 86 and/or after adjuvant chemotherapy in 70 cases using the RT-PCR-based AdnaTest and found higher CTC positivity rate after chemotherapy (27% vs. 19%, respectively) \[[@CR9]\]. Positive CTC status correlated with shorter OS, independent of the time point of blood sampling (*p* = 0.0054 before surgery and *p* = 0.047 after chemotherapy).

Conclusions {#Sec10}
===========

In this prospective translational study, we show that hematogenous tumor cell dissemination is a common phenomenon in ovarian, fallopian tube and primary peritoneal carcinoma and is not restricted to patients with high-grade or node-positive disease. With regard to the clinical relevance of this phenomenon, CTC detection before start of adjuvant treatment significantly predicted shorter OS and PFS. However, since CTC counts declined rapidly during systemic therapy, this approach does not seem likely to identify patients at particular risk of relapse. Future research is required to fully understand the potential of CTC detection and characterization in patients with these tumor entities.
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